The anti-VEGF economics are moving against the practice
The three dominant agents — bevacizumab (Avastin, used off-label), ranibizumab (Lucentis), and aflibercept (Eylea) — together accounted for more than $3.5 billion of annual Medicare Part B spending, and each has now passed its key patent milestone (Avastin 2019, Lucentis 2020, Eylea 2023), opening the door to biosimilars. As exclusivity fades, ASPs and Medicare allowables decline, and the drug margin under buy-and-bill declines with them.
At the same time, payers increasingly impose step therapy — often requiring bevacizumab, or now a biosimilar, before a branded agent — a practice the American Society of Retina Specialists has opposed as inappropriate interference with physician choice. For the practice, the combined effect is a thinner spread, more administrative friction, and more places for a claim to be underpaid or denied.
Retina practices cannot control ASP erosion, but they can control what they collect on the work they do. Accurate drug and biosimilar coding, disciplined waste capture, and a documented response to step therapy convert a shrinking, error-prone drug line into revenue the practice actually keeps.
Defending and recovering the retina drug line
Two fronts: recover what is being underpaid today, and manage step therapy so it does not quietly erode both margin and care.
Code biosimilars and agents precisely
Each anti-VEGF product and biosimilar carries its own HCPCS/Q-code and ASP-based rate. As biosimilars enter the mix, coding errors and stale rate tables become a direct source of underpayment — reconcile them continuously.
Capture single-dose-vial waste
Anti-VEGF vials are single-dose; discarded amounts are billable with the JW modifier and zero-waste claims require JZ. Unbilled waste is recoverable revenue, and missing modifiers drive avoidable denials.
Manage step therapy deliberately
Track each payer’s protocol, document medical necessity and step-therapy exceptions, and appeal inappropriate denials — protecting both the clinically indicated agent and the associated revenue.
Audit administration reimbursement
Confirm the injection administration is paid to contract and not bundled or downcoded — the fee matters more as the drug spread thins.
As the drug margin compresses, the accuracy of every line matters more, not less. What used to be absorbed by a comfortable spread now falls straight to the bottom line — which makes coding, waste capture, and step-therapy discipline a margin strategy, not a billing detail.
The spread is shrinking. The leaks do not have to.
The economics of anti-VEGF care are moving in the payer’s favor — falling ASPs, biosimilar substitution, and step-therapy protocols that constrain the practice’s choices. None of that is within a retina group’s control. What is within its control is how much of the earned revenue it actually collects.
As the drug spread thins, precision becomes the margin strategy. Accurate biosimilar coding, disciplined single-dose-vial waste capture, and a documented response to step therapy turn an error-prone, shrinking drug line into revenue the practice keeps — and keep the clinically indicated agent in the room.
Sources
- American Society of Retina Specialists, “Physician Choice of Medication” and recommendations on biosimilar anti-VEGF products and step therapy.
- CMS Medicare Part B drug spending data and ASP methodology; Retinal Physician / Retina Today, anti-VEGF biosimilar landscape.
- CMS, JW and JZ Modifier Billing Guidelines (single-dose container waste billing).
- Fulcrum Health Partners analysis and FulcrumIQ variance-recovery methodology.